{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:55:33Z","timestamp":1779195333167,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejca.2023.113425","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:01:29Z","timestamp":1700514089000},"page":"113425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy"],"prefix":"10.1016","volume":"196","author":[{"given":"Nikolaus B.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max M.","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"K\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-5132","authenticated-orcid":false,"given":"Lydia","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Fuch\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Ring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-9596","authenticated-orcid":false,"given":"Ramon","family":"St\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Zellweger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Kimeswenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Oellinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-1577","authenticated-orcid":false,"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Klumpp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Hoetzenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-1677","authenticated-orcid":false,"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cozzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-780X","authenticated-orcid":false,"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4340-9706","authenticated-orcid":false,"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas K.","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6892","key":"10.1016\/j.ejca.2023.113425_bib1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2023.113425_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0248-4900(01)01125-X","article-title":"The Raf\/MEK\/ERK pathway: new concepts of activation","volume":"93","author":"Peyssonnaux","year":"2001","journal-title":"Biol Cell"},{"issue":"1","key":"10.1016\/j.ejca.2023.113425_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2023.113425_bib4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113425_bib5","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113425_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2023.113425_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002350","article-title":"Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.113425_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113425_bib9","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2014"},{"key":"10.1016\/j.ejca.2023.113425_bib10","unstructured":"Alboukadel Kassambara. ggpubr: 'ggplot2' Based Publication Ready Plots. In: R package version 0.4.0.; 2020."},{"issue":"9","key":"10.1016\/j.ejca.2023.113425_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092359","article-title":"Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients","volume":"12","author":"Hilke","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ejca.2023.113425_bib12","first-page":"756","article-title":"Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation","volume":"63","author":"Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.ejca.2023.113425_bib13","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/cncr.29586","article-title":"Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors","volume":"121","author":"Menzies","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.113425_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-021-00792-8","article-title":"Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors","volume":"16","author":"Gassenmaier","year":"2021","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113425_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.","volume":"15","author":"Larkin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113425_bib16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","article-title":"Modeled prognostic subgroups for survival and treatment outcomes in BRAF v600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials","volume":"4","author":"Hauschild","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.113425_bib17","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113425_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/8755122517747089","article-title":"Treatment sequencing in advanced BRAF-mutant melanoma patients: current practice in the United States","volume":"34","author":"Audibert","year":"2018","journal-title":"J Pharm Technol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113425_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176080","article-title":"Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: introducing mathematical modelling of kinetics into the therapeutic decision","volume":"12","author":"Hartung","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejca.2023.113425_bib20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ejca.2013.12.015","article-title":"Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma","volume":"50","author":"Gaudy-Marqueste","year":"2014","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.113425_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2023.113425_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.113425_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113425_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/imt-2018-0208","article-title":"Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison","volume":"11","author":"Atkins","year":"2019","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.ejca.2023.113425_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092082","article-title":"The role of treatment sequencing with immune-checkpoint inhibitors and BRAF\/MEK inhibitors for response and survival of patients with BRAFV600-mutant metastatic melanoma-a retrospective, real-world cohort study","volume":"14","author":"Haist","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300727X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492300727X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:25Z","timestamp":1760733805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492300727X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":25,"alternative-id":["S095980492300727X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113425","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113425"}}